Literature DB >> 17414983

SF-36 outcomes and fusion rates after multilevel laminectomies and 1 and 2-level instrumented posterolateral fusions using lamina autograft and demineralized bone matrix.

Nancy E Epstein1, Joseph A Epstein.   

Abstract

Short-Form 36 (SF-36) outcomes and fusion rates were assessed after multilevel laminectomies and 1 (95 patients) or 2-level (45 patients) instrumented fusions. The posterolateral fusion mass consisted of lamina autograft and demineralized bone matrix (Osteofil/ICM: Sofamor Danek, Memphis, TN) in a 50:50 mix. SF-36 questionnaires were administered preoperatively and 3, 6, and 12 months postoperatively. Two independent neuroradiologists (blinded to study design) separately documented fusion on both dynamic x-rays and two-dimensional-computed tomography (2D-CT) studies performed 3, 6, and up to 12 months postoperatively until arthrodesis was demonstrated. Patients were followed an average of 3 years in both fusion series (minimum of 1.5 y). One-year postoperatively, comparably improved outcomes were observed for both groups on 6 of 8 Health Scales of the SF-36. 2D-CT studies documented 1-level fusion an average of 5.2 months (Standard Deviation 1.8) postoperatively in 88 (92.6%) of 95 cases, whereas dynamic x-rays confirmed fusion in 93 (98%) patients. For 2 patients undergoing 1-level fusions, both 2D-CT and dynamic x-ray documented pseudarthrosis/instability; both patients required secondary surgery an average of 8 months postoperatively. 2D-CT documented 2-level fusion an average of 6.1 months (Standard Deviation 1.9) postoperatively in 41 of 45 (91.2%) patients, whereas dynamic x-rays confirmed fusion in 43 (96%) patients. For 2 patients undergoing 2-level fusions, both 2D-CT and dynamic x-rays documented pseudarthrosis/instability; both patients required secondary fusion an average of 10 months postoperatively. High fusion rates and adequate outcomes were observed after multilevel laminectomies and 1 and 2-level instrumented posterolateral fusions performed using lamina autograft and demineralized bone matrix: Osteofil/ICM.

Entities:  

Mesh:

Year:  2007        PMID: 17414983     DOI: 10.1097/01.bsd.0000211261.36120.3e

Source DB:  PubMed          Journal:  J Spinal Disord Tech        ISSN: 1536-0652


  7 in total

1.  Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies.

Authors:  Abhijeet Kadam; Paul W Millhouse; Christopher K Kepler; Kris E Radcliff; Michael G Fehlings; Michael E Janssen; Rick C Sasso; James J Benedict; Alexander R Vaccaro
Journal:  Int J Spine Surg       Date:  2016-09-22

Review 2.  Use of demineralized bone matrix in spinal fusion.

Authors:  Konstantinos Tilkeridis; Panagiotis Touzopoulos; Athanasios Ververidis; Sotirios Christodoulou; Konstantinos Kazakos; Georgios I Drosos
Journal:  World J Orthop       Date:  2014-01-18

Review 3.  Improving the clinical evidence of bone graft substitute technology in lumbar spine surgery.

Authors:  Wellington K Hsu; M S Nickoli; J C Wang; J R Lieberman; H S An; S T Yoon; J A Youssef; D S Brodke; C M McCullough
Journal:  Global Spine J       Date:  2012-10-09

4.  Low reoperation rate following 336 multilevel lumbar laminectomies with noninstrumented fusions.

Authors:  Nancy Ellen Epstein
Journal:  Surg Neurol Int       Date:  2016-05-17

5.  The available evidence on demineralised bone matrix in trauma and orthopaedic surgery: A systematic review.

Authors:  J van der Stok; K A Hartholt; D A L Schoenmakers; J J C Arts
Journal:  Bone Joint Res       Date:  2017-07       Impact factor: 5.853

Review 6.  Allograft Versus Demineralized Bone Matrix in Instrumented and Noninstrumented Lumbar Fusion: A Systematic Review.

Authors:  Zorica Buser; Darrel S Brodke; Jim A Youssef; Elke Rometsch; Jong-Beom Park; S Tim Yoon; Jeffrey C Wang; Hans-Joerg Meisel
Journal:  Global Spine J       Date:  2017-10-25

Review 7.  Demineralized Bone Matrix Carriers and their Clinical Applications: An Overview.

Authors:  Hao Zhang; Li Yang; Xiong-Gang Yang; Feng Wang; Jiang-Tao Feng; Kun-Chi Hua; Qi Li; Yong-Cheng Hu
Journal:  Orthop Surg       Date:  2019-09-08       Impact factor: 2.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.